Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single Center, Open Label, Dose Escalation Phase I/IIa Study to Assess the Safety and Efficacy of an Intrathecal Administration of SCM-010 in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)

NCT03696485 is registered in ClinicalTrials.gov with Stem Cell Medicine Ltd. as lead sponsor.

NCT NCT03696485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03696485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single Center, Open Label, Dose Escalation Phase I/IIa Study to Assess the Safety and Efficacy of an Intrathecal Administration of SCM-010 in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)
Lead sponsor
Stem Cell Medicine Ltd.
Phase
Phase 1/2
Overall status
Withdrawn
Start date
February 1, 2024
Completion date
February 1, 2025
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

secondary progressive multiple sclerosis (spms)